Novo Nordisk (NOV) Stock Forecast & Price Target

Compare

388 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOV Analyst Ratings

Moderate Buy

7 Buy

4 Hold

2 Sell

Based on 13 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOV Stock 12 Month Forecast

Average Price Target

€80.96

▲(37.76%Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is €80.96 with a high forecast of €100.51 and a low forecast of €44.22. The average price target represents a 37.76% change from the last price of €58.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"€43","88":"€88","133":"€133","65.5":"€65.5","110.5":"€110.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100.50525,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€100.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.96300919,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€80.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.22231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€44.22</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,65.5,88,110.5,133],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.53,62.68194230769231,65.83388461538462,68.98582692307693,72.13776923076924,75.28971153846155,78.44165384615386,81.59359615384616,84.74553846153847,87.89748076923078,91.04942307692309,94.2013653846154,97.3533076923077,{"y":100.50525,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.53,61.178693014615384,62.827386029230766,64.47607904384616,66.12477205846153,67.77346507307692,69.42215808769231,71.07085110230769,72.71954411692307,74.36823713153845,76.01693014615384,77.66562316076923,79.3143161753846,{"y":80.96300919,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,59.53,58.352485384615385,57.17497076923077,55.99745615384616,54.81994153846154,53.642426923076926,52.46491230769231,51.28739769230769,50.109883076923076,48.93236846153846,47.75485384615385,46.57733923076923,45.39982461538462,{"y":44.22231,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":132.904,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.811,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.967,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.524,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.016,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.294,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.016,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€100.51

Average Price Target€80.96

Lowest Price Target€44.22

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jo WaltonUBS

UBS

€93.81

Buy

59.62%

Upside

Reiterated

07/11/25

Novo Nordisk (0QIU) Receives a Buy from UBS

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

€100.51

Buy

71.03%

Upside

Reiterated

07/09/25

Deutsche Bank Remains a Buy on Novo Nordisk (0QIU)

Sachin JainBank of America Securities

Bank of America Securities

€113.91→€73.71

Buy

25.42%

Upside

Reiterated

07/01/25

Bank of America Securities Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Richard VosserJ.P. Morgan

J.P. Morgan

€87.11

Buy

48.22%

Upside

Reiterated

06/30/25

J.P. Morgan Remains a Buy on Novo Nordisk (0QIU)

James QuigleyGoldman Sachs

Goldman Sachs

€103.86→€99.84

Buy

69.89%

Upside

Reiterated

06/30/25

Goldman Sachs Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Thibault BoutherinMorgan Stanley

Morgan Stanley

€73.71

Hold

25.42%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

David EvansKepler Capital

Kepler Capital

€84.43

Buy

43.66%

Upside

Reiterated

06/23/25

Kepler Capital Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

Benjamin Jackson CFAJefferies

Jefferies

€55.62

Sell

-5.37%

Downside

Reiterated

06/23/25

Novo Nordisk (0QIU) Gets a Sell from Jefferies

Emily FieldBarclays

Barclays

€93.81

Buy

59.62%

Upside

Reiterated

06/23/25

Florent CespedesBernstein

Bernstein

€83.09

Hold

41.38%

Upside

Reiterated

06/12/25

Bernstein Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Kerry HolfordBerenberg Bank

Berenberg Bank

€81.75

Hold

39.10%

Upside

Reiterated

05/16/25

Berenberg Bank Remains a Hold on Novo Nordisk (0QIU)

Elmar KrausDZ BANK AG

DZ BANK AG

―

Hold

―

Reiterated

05/08/25

DZ BANK AG Remains a Hold on Novo Nordisk (0QIU)

Nico ChenDBS

DBS

€44.23

Sell

-24.75%

Downside

Downgraded

04/24/25

Novo Nordisk downgraded to Sell from Buy at DBS BankNovo Nordisk downgraded to Sell from Buy at DBS Bank

Eric Le BerrigaudStifel Nicolaus

Stifel Nicolaus

€104.53→€93.81

Hold

59.62%

Upside

Downgraded

03/03/25

Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel

Seamus FernandezGuggenheim

Guggenheim

€106.54→€106.94

Buy

81.97%

Upside

Reiterated

01/17/25

Novo Nordisk price target raised to DKK 798 from DKK 795 at GuggenheimNovo Nordisk price target raised to DKK 798 from DKK 795 at Guggenheim

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jo WaltonUBS

UBS

€93.81

Buy

59.62%

Upside

Reiterated

07/11/25

Novo Nordisk (0QIU) Receives a Buy from UBS

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

€100.51

Buy

71.03%

Upside

Reiterated

07/09/25

Deutsche Bank Remains a Buy on Novo Nordisk (0QIU)

Sachin JainBank of America Securities

Bank of America Securities

€113.91→€73.71

Buy

25.42%

Upside

Reiterated

07/01/25

Bank of America Securities Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Richard VosserJ.P. Morgan

J.P. Morgan

€87.11

Buy

48.22%

Upside

Reiterated

06/30/25

J.P. Morgan Remains a Buy on Novo Nordisk (0QIU)

James QuigleyGoldman Sachs

Goldman Sachs

€103.86→€99.84

Buy

69.89%

Upside

Reiterated

06/30/25

Goldman Sachs Sticks to Their Buy Rating for Novo Nordisk (0QIU)

Thibault BoutherinMorgan Stanley

Morgan Stanley

€73.71

Hold

25.42%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

David EvansKepler Capital

Kepler Capital

€84.43

Buy

43.66%

Upside

Reiterated

06/23/25

Kepler Capital Reaffirms Their Buy Rating on Novo Nordisk (0QIU)

Benjamin Jackson CFAJefferies

Jefferies

€55.62

Sell

-5.37%

Downside

Reiterated

06/23/25

Novo Nordisk (0QIU) Gets a Sell from Jefferies

Emily FieldBarclays

Barclays

€93.81

Buy

59.62%

Upside

Reiterated

06/23/25

Florent CespedesBernstein

Bernstein

€83.09

Hold

41.38%

Upside

Reiterated

06/12/25

Bernstein Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Kerry HolfordBerenberg Bank

Berenberg Bank

€81.75

Hold

39.10%

Upside

Reiterated

05/16/25

Berenberg Bank Remains a Hold on Novo Nordisk (0QIU)

Elmar KrausDZ BANK AG

DZ BANK AG

―

Hold

―

Reiterated

05/08/25

DZ BANK AG Remains a Hold on Novo Nordisk (0QIU)

Nico ChenDBS

DBS

€44.23

Sell

-24.75%

Downside

Downgraded

04/24/25

Novo Nordisk downgraded to Sell from Buy at DBS BankNovo Nordisk downgraded to Sell from Buy at DBS Bank

Eric Le BerrigaudStifel Nicolaus

Stifel Nicolaus

€104.53→€93.81

Hold

59.62%

Upside

Downgraded

03/03/25

Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel

Seamus FernandezGuggenheim

Guggenheim

€106.54→€106.94

Buy

81.97%

Upside

Reiterated

01/17/25

Novo Nordisk price target raised to DKK 798 from DKK 795 at GuggenheimNovo Nordisk price target raised to DKK 798 from DKK 795 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

1 Month

xxx

Success Rate

35/58 ratings generated profit

Average Return

+1.17%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.34% of your transactions generating a profit, with an average return of +1.17% per trade.

3 Months

xxx

Success Rate

39/59 ratings generated profit

Average Return

+3.81%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.10% of your transactions generating a profit, with an average return of +3.81% per trade.

1 Year

Emily FieldBarclays

Success Rate

25/34 ratings generated profit

Average Return

+22.45%

reiterated a buy rating 22 days ago

Copying Emily Field's trades and holding each position for 1 Year would result in 73.53% of your transactions generating a profit, with an average return of +22.45% per trade.

2 Years

xxx

Success Rate

34/58 ratings generated profit

Average Return

+22.10%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 58.62% of your transactions generating a profit, with an average return of +22.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOV Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOV has received 31 Buy Ratings, 7 Hold Ratings, and 2 Sell Ratings. NOV average Analyst price target in the past 3 months is 80.96.

Each month's total comprises the sum of three months' worth of ratings.

NOV Financial Forecast

NOV Earnings Forecast

Next quarter’s earnings estimate for NOV is €0.80 with a range of €0.72 to €0.84. The previous quarter’s EPS was €0.88. NOV beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.85% of the time in the same period. In the last calendar year NOV has Preformed in-line its overall industry.

NOV Sales Forecast

Next quarter’s sales forecast for NOV is €10.32B with a range of €9.80B to €10.71B. The previous quarter’s sales results were €10.46B. NOV beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.06% of the time in the same period. In the last calendar year NOV has Preformed in-line its overall industry.

NOV Stock Forecast FAQ

What is DE:NOV’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk A/S (UK)’s 12-month average price target is 80.96.

What is DE:NOV’s upside potential, based on the analysts’ average price target?

Novo Nordisk A/S (UK) has 37.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk A/S (UK) a Buy, Sell or Hold?

Novo Nordisk A/S (UK) has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 4 hold ratings and 2 sell ratings.

What is Novo Nordisk A/S (UK)’s share price target?

The average share price target for Novo Nordisk A/S (UK) is 80.96. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €100.51 ,and the lowest forecast is €44.22. The average share price target represents 37.76% Increase from the current price of €58.77.

What do analysts say about Novo Nordisk A/S (UK)?

Novo Nordisk A/S (UK)’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Novo Nordisk A/S (UK)?

To buy shares of DE:NOV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novo Nordisk (NOV) Stock Forecast & Price Target

NOV Analyst Ratings

NOV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

NOV Analyst Recommendation Trends

NOV Financial Forecast

NOV Earnings Forecast

NOV Sales Forecast

NOV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts